Expand IVVD Menu
IVVD MENU

IVVD Latest Press Releases

-- January 8, 2026 --

Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights Globe Newswire 7:01 AM

-- December 23, 2025 --

Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID Globe Newswire 7:05 AM
Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID Globe Newswire 7:01 AM

-- November 25, 2025 --

Invivyd to Participate at the 8th Annual Evercore Healthcare Conference Globe Newswire 7:01 AM

-- November 24, 2025 --

Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness Globe Newswire 7:01 AM

-- November 17, 2025 --

Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants Globe Newswire 10:40 PM
Invivyd Announces Proposed Public Offering of Common Stock Globe Newswire 4:01 PM

-- November 6, 2025 --

Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights Globe Newswire 7:01 AM

-- November 3, 2025 --

Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025 Globe Newswire 4:01 PM

-- October 28, 2025 --

Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID Globe Newswire 7:01 AM

-- October 6, 2025 --

Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID Globe Newswire 7:01 AM

-- September 24, 2025 --

Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors Globe Newswire 4:01 PM

-- September 17, 2025 --

Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer Globe Newswire 7:01 AM

-- September 4, 2025 --

SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At RECOVER-TLC Workshop September 9-10, 2025 Globe Newswire 7:01 AM

-- August 30, 2025 --

? ?????, ??? ? ???? ?? ??? ??? ???? ?? Surbhi Jain 3:44 PM

-- August 27, 2025 --

Invivyd to Participate in Upcoming Investor Conferences Globe Newswire 7:01 AM

-- August 22, 2025 --

Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Shares Globe Newswire 12:00 PM

-- August 20, 2025 --

Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants Globe Newswire 11:58 PM
Invivyd Announces Proposed Public Offering of Common Stock Globe Newswire 4:01 PM

-- August 18, 2025 --

Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG ("Stratus") Globe Newswire 4:32 PM

-- August 14, 2025 --

Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights Globe Newswire 4:49 PM
Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19 Globe Newswire 4:47 PM
Market Data Delayed 15 Minutes